Dr. Bernardini is the Division Head of Gynecologic Oncology at the University Health Network and Mount Sinai Hospital, an Associate Professor in the Department of Obstetrics and Gynecology at the University of Toronto, and an Associate Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital. A graduate of the University of Western Ontario, Dr. Bernardini completed his residency at the University of Toronto and obtained a Master’s degree in Laboratory and Pathobiology, which was followed by a combined fellowship in Gynecologic Oncology at the University of Toronto and Duke University Medical Centre. Dr. Bernardini is an associate professor at the University of Toronto and has received Research and Teaching awards such as the 2018 ‘Senior Merit Award’ (research) and the 2014 ‘Award for Teaching Excellence.’ He leads the UHN robotic surgery program and is the co-director of the Women’s College Prevent Ovarian Cancer Program. His research interests include: understanding the role of precursor lesions in high grade serous ovarian cancer, as well as cytoreductive surgery for later stage disease. He co-leads the ovarian cytoreductive program as well as CANSTIC, a pan-Canadian study looking at treatment and outcomes of ovarian pre-cursor lesions and is Lead Investigator of the Early Stage Cohort for the CANSTAMP trial investigating new approaches to front-line therapy in serous and/or p53 abnormal/mutant endometrial cancer.
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Obstetrics and Gynecology, University of Toronto
Associate Professor, Institute of Medical Sciences, University of Toronto
Associate Scientist, Department of Obstetrics and Gynaecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital